Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis; SPINRAZA for spinal muscular atrophy; SKYCLARYS for Friedreich's Ataxia; QALSODY for amyotrophic lateral sclerosis; FUMADERM for plaque psoriasis; BENEPALI, an etanercept biosimilar; and IMRALDI, an adalimumab biosimilar. Biogen Inc. focuses on addressing unmet medical needs in the fields of neurology, including multiple sclerosis, spinal muscular atrophy, and rare diseases like Friedreich's Ataxia and ALS. Its portfolio emphasizes innovative treatments that target the underlying mechanisms of these debilitating conditions, serving patients through specialized healthcare channels worldwide. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen Inc. plays a vital role in advancing biopharmaceutical solutions for complex neurological disorders.
Every rating change, who made it, and what it moved from.
Sign in to viewCreate a free accountFree account. No card required.
Analyst price targets — high, low, median and where it sits now.
Sign in to viewCreate a free accountFree account. No card required.
Analyst price targets — high, low, median and the upside from here.
Sign in to viewCreate a free accountFree account. No card required.
DCF, Piotroski, Altman Z and returns scores, in one grade.
Sign in to viewCreate a free accountFree account. No card required.
Quarterly revenue and EPS estimates, with the history of beats.
Sign in to viewCreate a free accountFree account. No card required.
How this ticker has traded month by month over the last decade.
Sign in to viewCreate a free accountFree account. No card required.